We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$25.4B
1-Year Est. Return
38.46%
This Fund
S&P 500
This Quarter
Est. Return
-3.12%
1 Year Est. Return
+38.46%
3 Year Est. Return
+154.38%
5 Year Est. Return
+223.79%
10 Year Est. Return
+923.25%
AUM
$19.3B
AUM Growth
-$1.05B
(-5.2%)
Cap. Flow
-$77.1M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
26.03%
Holding
1,444
New
138
Increased
405
Reduced
531
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$224M |
| 2 |
Brown-Forman Class B
BF.B
|
+$140M |
| 3 |
UnitedHealth
UNH
|
+$132M |
| 4 |
Monolithic Power Systems
MPWR
|
+$108M |
| 5 |
Oracle
ORCL
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$134M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 3 |
Micron Technology
MU
|
+$122M |
| 4 |
Pfizer
PFE
|
+$120M |
| 5 |
Microsoft
MSFT
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.43% |
| 2 | Healthcare | 14.49% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Sutro Biopharma
STRO
$350M
| $381K | ﹤0.01% |
6,868
| – | – |
|
|
BPMC
1002
DELISTED
Blueprint Medicines
BPMC
| $380K | ﹤0.01% |
+5,762
| New | +$370K |
|
1003
Flywire
FLYW
$2.16B
| $380K | ﹤0.01% |
+16,570
| New | +$395K |
|
|
NFBK
1004
DELISTED
Northfield Bancorp
NFBK
| $379K | ﹤0.01% |
26,485
+4,850
| +22% | +$70.2K |
|
|
SIVB
1005
DELISTED
SVB Financial Group
SIVB
| $379K | ﹤0.01% |
1,128
+361
| +47% | +$145K |
|
1006
PMV Pharmaceuticals
PMVP
$67.7M
| $378K | ﹤0.01% |
31,790
+320
| +1% | +$4.62K |
|
1007
US Foods
USFD
$23.9B
| $375K | ﹤0.01% |
14,188
| – | – |
|
|
ITCI
1008
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $375K | ﹤0.01% |
+8,054
| New | +$421K |
|
1009
Unitil
UTL
$996M
| $373K | ﹤0.01% |
8,032
-9,318
| -54% | -$504K |
|
1010
Cerus
CERS
$562M
| $372K | ﹤0.01% |
103,232
+22,019
| +27% | +$105K |
|
|
AEL
1011
DELISTED
American Equity Investment Life Holding Company
AEL
| $372K | ﹤0.01% |
9,964
-570
| -5% | -$21.4K |
|
1012
Legend Biotech
LEGN
$4.02B
| $371K | ﹤0.01% |
9,087
| – | – |
|
1013
Prothena Corp
PRTA
$473M
| $370K | ﹤0.01% |
+6,106
| New | +$193K |
|
|
CMRC
1014
Commerce.com Inc Series 1
CMRC
$181M
| $368K | ﹤0.01% |
24,898
| – | – |
|
1015
Mirum Pharmaceuticals
MIRM
$6.05B
| $368K | ﹤0.01% |
17,533
-12,087
| -41% | -$291K |
|
1016
Entergy
ETR
$49.9B
| $367K | ﹤0.01% |
7,286
-2,500
| -26% | -$143K |
|
1017
RLX Technology
RLX
$2.49B
| $367K | ﹤0.01% |
+349,655
| New | +$535K |
|
1018
Interface
TILE
$2.25B
| $367K | ﹤0.01% |
40,807
+15,496
| +61% | +$188K |
|
1019
Peoples Bancorp
PEBO
$1.49B
| $365K | ﹤0.01% |
12,610
| – | – |
|
1020
Ziff Davis
ZD
$1.9B
| $365K | ﹤0.01% |
5,326
-2,808
| -35% | -$221K |
|
1021
Moelis & Co
MC
$4.94B
| $364K | ﹤0.01% |
10,777
-35,286
| -77% | -$1.48M |
|
|
EVRI
1022
DELISTED
Everi Holdings
EVRI
| $363K | ﹤0.01% |
22,409
-2,736
| -11% | -$50.4K |
|
1023
PTC
PTC
$16.1B
| $363K | ﹤0.01% |
+3,470
| New | +$396K |
|
1024
Stoke Therapeutics
STOK
$2.12B
| $362K | ﹤0.01% |
28,223
| – | – |
|
1025
Usana Health Sciences
USNA
$251M
| $359K | ﹤0.01% |
6,406
-2,085
| -25% | -$138K |
|
Similar funds
VAI
Los Angeles Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Los Angeles Capital Management held 1,444 positions worth $19.3B, down 5.2% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Los Angeles Capital Management's Q3 2022 filing shows 138 new, 405 increased, 531 reduced and 234 closed positions. Its largest new stake was Neurocrine Biosciences: 791,966 shares worth $84.1M. The largest sale was Alphabet (Google) Class C, an estimated $134M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- Los Angeles Capital Management's largest Q3 2022 buy was Neurocrine Biosciences: 791,966 shares worth $84.1M.
- Los Angeles Capital Management added most to Broadcom in Q3 2022, an estimated $224M increase.
- Los Angeles Capital Management's biggest Q3 2022 reduction was Alphabet (Google) Class C, cutting an estimated $134M.
- Los Angeles Capital Management fully exited D.R. Horton in Q3 2022, selling an estimated $37.1M.
- Los Angeles Capital Management's ten largest holdings make up 26% of its $19.3B portfolio in Q3 2022.
- Los Angeles Capital Management opened 138 new positions and closed 234 in Q3 2022.
- Los Angeles Capital Management's portfolio value fell 5.2% quarter-over-quarter to $19.3B.
Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.